NBIX - Neurocrine Biosciences Non-GAAP EPS of $1.24 misses by $0.20 revenue of $412M beats by $3.04M
- Neurocrine Biosciences press release ( NASDAQ: NBIX ): Q4 Non-GAAP EPS of $1.24 misses by $0.20 .
- Revenue of $412M (+32.1% Y/Y) beats by $3.04M .
- INGREZZA fourth quarter and fiscal 2022 net product sales were $399 million and $1.43 billion, respectively
- INGREZZA ® (valbenazine) 2023 Net Product Sales Guidance of $1.67 - $1.77 Billion
- INGREZZA fourth quarter net product sales and total prescriptions grew 33% and 29%, respectively, vs. fourth quarter of 2021
For further details see:
Neurocrine Biosciences Non-GAAP EPS of $1.24 misses by $0.20, revenue of $412M beats by $3.04M